CAMKK2 and ovarian cancer: A previous study reported that the pharmacological inhibition of AMPK decreased the viability of ovarian cancer spheroids; however, STO-609, the inhibitor used in that study, targets calcium/calmodulin-dependent protein kinase kinase beta (CAMKKβ), an upstream kinase of AMPK [28].